By Peter Nurse
Investing.com -- Stocks in focus in premarket trade on Thursday, September 22nd. Please refresh for updates.
Lennar (NYSE:LEN) stock fell 1.5% after the homebuilder reported better-than-expected third-quarter results, boosted by record high prices, but new home sales disappointed.
H.B. Fuller (NYSE:FUL) stock rose 2.2% after the adhesives company beat quarterly earnings expectations, citing “robust pricing actions to recover unprecedented raw material cost inflation.”
Accenture (NYSE:ACN) stock fell 0.3% after the IT services firm forecast first-quarter revenue below expectations, weighed down by IT spending cuts amid high inflation and impact from a stronger dollar.
Eli Lilly (NYSE:LLY) stock rose 1.8% after UBS upgraded its investment stance on the pharma company to ‘buy’ from ‘neutral’, citing the likely benefits of futures sales of a key weight loss drug.
Salesforce (NYSE:CRM) stock rose 2.5% after the cloud-based software company announced plans for a 25% operating margin by 2026, seeking to operate much more efficiently.
Target (NYSE:TGT) stock rose 0.2% after the big-box retailer announced plans to hire up to 100,000 seasonal workers for the holiday season and start offering festive deals earlier than ever.
Manchester United (NYSE:MANU) stock will be in focus after the English soccer club reported a net loss of 70.7 million pounds for the three months to June 30, a narrowing from a loss of 107.7 million pounds a year earlier.
Nike (NYSE:NKE) stock rose 0.7% after RBC initiated coverage of the retailer at ‘outperform’, saying the “100lb gorilla in sportswear” is set to surge almost 30%.
Novavax (NASDAQ:NVAX) stock fell 5.7% after JPMorgan downgraded its stance on the drug maker to 'underweight' from 'neutral'. citing reduced vaccine demand.
Begin trading today! Create an account by completing our form
At One Financial Markets we are committed to safeguarding your privacy.
Please see our Privacy Policy for details about what information is collected from you and why it is collected. We do not sell your information or use it other than as described in the Policy.
Please note that it is in our legitimate business interest to send you certain marketing emails from time to time. However, if you would prefer not to receive these you can opt-out by ticking the box below.
Alternatively, you can use the unsubscribe link at the bottom of the Demo account confirmation email or any subsequent emails we send.
By completing the form and downloading the platform you agree with the use of your personal information as detailed in the Policy.